How Do Peptides Work? Mechanisms of Action Explained (2026)

Overview

Peptides are short chains of amino acids — typically between 2 and 50 residues — that serve as signaling molecules throughout the human body. Unlike larger proteins, their smaller size allows them to interact with specific cell surface receptors and sometimes penetrate tissues more readily, making them attractive candidates for therapeutic development. Understanding how peptides work at the molecular level is essential for evaluating their potential applications, from FDA-approved GLP-1 receptor agonists like Semaglutide and Tirzepatide to investigational healing compounds like BPC-157 and TB-500. This guide explains the fundamental science behind peptide mechanisms of action, including how they are structured, how they bind to receptors, how they enter the body, and why certain peptides are effective for specific applications like growth hormone release, tissue repair, and weight management. All information presented here is educational and does not constitute medical advice.

Peptide Bonds and Molecular Structure

At the most fundamental level, a peptide is defined by its peptide bonds — covalent chemical bonds formed between the carboxyl group of one amino acid and the amino group of the next, releasing a molecule of water in the process (a condensation reaction). This bond forms the backbone of every peptide chain and determines its primary structure: the linear sequence of amino acids. While the primary sequence dictates which receptors a peptide can interact with, the three-dimensional folding pattern (secondary and tertiary structure) determines how effectively it binds. Short peptides of 2-10 amino acids (oligopeptides) tend to be flexible and may adopt multiple conformations in solution, while longer peptides approaching 40-50 residues often fold into more stable structures like alpha-helices or beta-sheets. This structural behavior directly impacts biological activity. For example, GHK-Cu is a tripeptide (just three amino acids: glycine-histidine-lysine) that naturally complexes with copper ions, and this metal-peptide interaction is critical to its biological activity in wound healing and collagen synthesis. By contrast, Semaglutide is a 31-amino-acid peptide with a fatty acid side chain that enables it to bind albumin in the bloodstream, extending its half-life from minutes to approximately one week. The relationship between structure and function is the foundation of all peptide pharmacology — modifying even a single amino acid can dramatically alter a peptide's receptor affinity, stability, and therapeutic profile.

Receptor Binding and Cell Signaling

The primary mechanism by which peptides exert biological effects is receptor binding. Most therapeutic peptides act as ligands — molecules that bind to specific receptor proteins embedded in cell membranes. This binding event triggers a conformational change in the receptor that initiates an intracellular signaling cascade, ultimately altering gene expression, enzyme activity, or ion channel behavior within the target cell. The specificity of this interaction is remarkably precise: a peptide's amino acid sequence creates a unique three-dimensional shape that fits into a receptor binding pocket much like a key fits a lock. G-protein coupled receptors (GPCRs) are the most common target for peptide therapeutics. When a peptide binds a GPCR, it activates intracellular G-proteins that trigger second messenger systems — cyclic AMP (cAMP), inositol triphosphate (IP3), or calcium ions — which amplify the signal and produce the cellular response. For example, when Sermorelin or Ipamorelin bind to the growth hormone-releasing hormone receptor (GHRH-R) on pituitary somatotroph cells, they activate the cAMP pathway, which stimulates growth hormone synthesis and secretion. Similarly, GLP-1 receptor agonists like Semaglutide bind to GLP-1 receptors on pancreatic beta cells, activating cAMP-dependent pathways that enhance insulin secretion in a glucose-dependent manner. Some peptides act through receptor tyrosine kinases or other receptor types, but the GPCR pathway dominates peptide pharmacology. Understanding which receptor a peptide targets — and what downstream signaling it activates — is essential for predicting both its therapeutic effects and potential side effects.

• Peptides bind specific cell surface receptors, triggering intracellular signaling cascades
• G-protein coupled receptors (GPCRs) are the most common target for therapeutic peptides
• Second messenger systems (cAMP, IP3, calcium) amplify the receptor-binding signal inside cells
• Receptor specificity determines which tissues and biological processes a peptide affects
• The same signaling mechanism explains both intended effects and potential side effects

Routes of Administration: How Peptides Enter the Body

How a peptide enters the body significantly affects its bioavailability, onset of action, and therapeutic efficacy. The most common route for peptide therapeutics is subcutaneous injection — a shallow injection into the fatty tissue just beneath the skin. This route allows peptides to bypass the gastrointestinal tract entirely, avoiding the digestive enzymes that would rapidly degrade most peptide chains. Subcutaneous injection provides relatively consistent absorption, typically reaching peak blood levels within 1-4 hours depending on the peptide's molecular weight and formulation. This is the standard delivery method for compounds like Semaglutide, Tirzepatide, CJC-1295, Ipamorelin, Sermorelin, and BPC-157 in injectable form. Intravenous (IV) injection delivers peptides directly into the bloodstream for immediate effect but requires clinical administration and is primarily used in hospital or clinic settings. Intranasal delivery has emerged as a practical route for certain small peptides that can cross the nasal mucosa, offering the advantage of non-invasive administration and, for some compounds, a more direct pathway to the central nervous system. Oral administration is the most convenient route but also the most challenging for peptides, as gastric acid and proteolytic enzymes in the stomach and small intestine rapidly degrade most peptide bonds. Oral semaglutide (Rybelsus) overcame this challenge using a specialized absorption enhancer (SNAC) that protects the peptide and facilitates absorption across the gastric lining — a significant pharmaceutical achievement. Topical application is used for peptides like GHK-Cu in skin care formulations, though penetration through the skin barrier limits the depth of tissue reached. Each administration route represents a trade-off between convenience, bioavailability, and the specific therapeutic target. Our reconstitution calculator can help determine proper preparation methods for injectable peptides.

• Subcutaneous injection — most common; avoids GI degradation, consistent absorption over 1-4 hours
• Intravenous — immediate bioavailability but requires clinical setting
• Intranasal — non-invasive, potential CNS access for certain small peptides
• Oral — most convenient but requires specialized formulations to survive digestive enzymes
• Topical — useful for skin-targeting peptides like GHK-Cu but limited tissue penetration

Bioavailability Challenges and Peptide Engineering

Bioavailability — the proportion of an administered peptide that reaches systemic circulation in active form — is the central pharmacological challenge in peptide therapeutics. Native (unmodified) peptides typically have poor bioavailability because the human body is extremely efficient at breaking down peptide chains. Proteolytic enzymes in the blood, liver, kidneys, and gastrointestinal tract can degrade unmodified peptides within minutes, resulting in half-lives too short for practical therapeutic use. This is why pharmaceutical development focuses heavily on peptide engineering strategies that extend stability and duration of action. Amino acid substitution is one common approach: replacing natural L-amino acids with their D-amino acid mirror images at vulnerable positions makes the peptide resistant to enzymatic cleavage because proteases are stereospecific and cannot efficiently cleave D-amino acid bonds. PEGylation — attaching polyethylene glycol (PEG) chains to a peptide — increases its hydrodynamic size, reducing renal clearance and shielding it from enzymatic degradation. Lipidation, the strategy used in Semaglutide, involves attaching a fatty acid chain that binds reversibly to albumin in the blood, creating a circulating reservoir that slowly releases active peptide. Cyclization — connecting the ends of a linear peptide to form a ring structure — restricts conformational flexibility and dramatically improves resistance to exopeptidases. These engineering approaches have transformed peptide therapeutics from compounds requiring multiple daily injections to once-weekly or even less frequent dosing regimens, which is critical for patient adherence in chronic conditions like obesity and diabetes.

• Native peptides often have half-lives of minutes due to rapid enzymatic degradation
• D-amino acid substitution blocks protease cleavage at vulnerable bond positions
• PEGylation increases molecular size, reducing kidney filtration and enzyme access
• Lipidation (e.g., Semaglutide) enables albumin binding for extended circulation time
• Cyclization improves stability by restricting the peptide's conformational flexibility
• These modifications have enabled once-weekly dosing for compounds that would otherwise require multiple daily injections

Growth Hormone Secretagogues: Stimulating the Pituitary

Growth hormone secretagogues (GHS) are a class of peptides that stimulate the pituitary gland to release endogenous growth hormone (GH), rather than providing exogenous GH directly. This distinction is pharmacologically important because secretagogues preserve the body's natural pulsatile GH release pattern, which is associated with fewer side effects than continuous exogenous GH administration. Two primary receptor pathways mediate GH secretion from pituitary somatotroph cells. The first is the GHRH receptor pathway, targeted by peptides like Sermorelin and CJC-1295. These peptides mimic growth hormone-releasing hormone (GHRH) produced in the hypothalamus, binding to GHRH receptors and activating adenylyl cyclase, which raises intracellular cAMP and triggers GH gene transcription and secretion. CJC-1295 is a modified GHRH analog with a drug affinity complex (DAC) that extends its half-life to approximately 6-8 days, enabling sustained GH elevation with less frequent dosing. The second pathway involves the ghrelin/GHS receptor (GHS-R1a), targeted by peptides like GHRP-6, GHRP-2, Ipamorelin, and the non-peptide compound MK-677 (ibutamoren). These ghrelin mimetics bind to GHS-R1a receptors on pituitary cells, activating phospholipase C and the IP3/calcium signaling cascade to trigger GH release. Ipamorelin is notable for its selectivity — it stimulates GH release with minimal effect on cortisol and prolactin, unlike less selective GHRPs. The combination of a GHRH analog (like CJC-1295) with a ghrelin mimetic (like Ipamorelin) is commonly discussed because the two pathways are synergistic: GHRH increases the amplitude of GH pulses while ghrelin receptor activation increases pulse frequency. Our dosage calculator provides reference ranges for these compounds based on published research protocols.

• GHRH pathway (Sermorelin, CJC-1295) — activates cAMP signaling in pituitary somatotrophs
• Ghrelin/GHS-R1a pathway (GHRP-6, GHRP-2, Ipamorelin, MK-677) — activates IP3/calcium signaling
• Secretagogues preserve natural pulsatile GH release patterns unlike exogenous GH
• CJC-1295 with DAC extends half-life to 6-8 days for sustained GH elevation
• Ipamorelin is the most selective GHRP, with minimal cortisol and prolactin effects
• GHRH + ghrelin mimetic combinations are synergistic — increasing both pulse amplitude and frequency

Healing Peptides: Tissue Repair Mechanisms

Healing peptides represent a distinct category that works primarily through tissue repair and regeneration pathways rather than receptor-mediated hormonal signaling. BPC-157 (Body Protection Compound-157), a 15-amino-acid peptide derived from human gastric juice, has demonstrated broad tissue-protective effects in preclinical models. Its proposed mechanism involves upregulation of vascular endothelial growth factor (VEGF), which promotes angiogenesis — the formation of new blood vessels at injury sites. Adequate blood supply is foundational to tissue repair in virtually every organ system, and BPC-157's pro-angiogenic effects may explain why preclinical studies have observed benefits across tendons, muscles, gut lining, and neural tissue. BPC-157 also appears to modulate the nitric oxide (NO) system and influence growth hormone receptor expression in fibroblasts, enhancing the cellular repair response at injury sites. TB-500 (Thymosin Beta-4) operates through a different but complementary mechanism. This 43-amino-acid peptide is a naturally occurring molecule involved in actin regulation — actin being a cytoskeletal protein critical for cell migration, a process essential for wound healing. TB-500 promotes cell migration to injury sites, supports new blood vessel formation, and reduces inflammation in damaged tissue. In preclinical models, it has shown effects on cardiac, dermal, and corneal tissue repair. GHK-Cu works at the gene expression level: research has identified over 4,000 genes whose expression is modulated by this copper-peptide complex, including genes involved in collagen synthesis, anti-inflammatory responses, and antioxidant enzyme production. The healing peptide category is distinct because these compounds primarily work through local tissue-level mechanisms rather than systemic hormonal pathways, though some (like BPC-157) appear to have both local and systemic effects. All healing peptide evidence remains preclinical — no completed human randomized controlled trials confirm these mechanisms in clinical settings.

• BPC-157 — upregulates VEGF for angiogenesis, modulates NO system, enhances growth hormone receptor expression
• TB-500 — promotes actin-dependent cell migration to injury sites, supports new blood vessel formation
• GHK-Cu — modulates expression of over 4,000 genes involved in repair, collagen synthesis, and antioxidant defense
• Healing peptides primarily work through local tissue mechanisms rather than systemic hormonal pathways
• All healing peptide evidence is preclinical — human clinical trial confirmation is pending

Weight Loss Peptide Mechanisms: GLP-1 Receptor Agonists

The most clinically validated peptide mechanism for weight management is GLP-1 receptor agonism, exemplified by Semaglutide (Wegovy/Ozempic) and the dual GIP/GLP-1 agonist Tirzepatide (Zepbound/Mounjaro). These peptides mimic the incretin hormone glucagon-like peptide-1 (GLP-1), which is naturally released by intestinal L-cells after eating. GLP-1 receptor agonists produce weight loss through multiple convergent mechanisms. In the pancreas, they bind GLP-1 receptors on beta cells and activate cAMP-dependent pathways that enhance glucose-dependent insulin secretion — meaning insulin is released only when blood sugar is elevated, reducing the risk of hypoglycemia. In the gastrointestinal tract, they slow gastric emptying by modulating vagal nerve signaling, which prolongs the sensation of fullness after meals. Critically, GLP-1 receptors are also expressed in the hypothalamus and brainstem — brain regions that regulate appetite and energy homeostasis. When GLP-1 agonists bind to these central receptors, they reduce hunger signals and increase satiety, leading to decreased caloric intake that accounts for the majority of observed weight loss. Tirzepatide adds activation of GIP (glucose-dependent insulinotropic polypeptide) receptors, which appear to provide additive metabolic benefits including enhanced insulin sensitivity and potentially increased energy expenditure — contributing to its superior weight loss results (up to 22.5% body weight in the SURMOUNT-1 trial). Retatrutide further adds glucagon receptor activation, which increases hepatic fat oxidation and energy expenditure. Understanding these layered mechanisms explains why multi-receptor agonists tend to produce greater weight loss than single-receptor compounds. Our half-life calculator can help illustrate the pharmacokinetic differences between these agents.

• Pancreatic effects — glucose-dependent insulin secretion via cAMP activation in beta cells
• Gastric effects — slowed emptying via vagal nerve modulation, prolonging post-meal fullness
• Central nervous system effects — reduced hunger and increased satiety through hypothalamic GLP-1 receptors
• Tirzepatide adds GIP receptor activation for enhanced insulin sensitivity and metabolic effects
• Retatrutide adds glucagon receptor activation for increased hepatic fat oxidation
• Multi-receptor agonists produce greater weight loss through converging complementary mechanisms

Peptide Stability and Half-Life

A peptide's half-life — the time required for its concentration in the body to decrease by 50% — is one of the most critical factors determining its therapeutic utility. Native peptide hormones often have extremely short half-lives: endogenous GLP-1 has a half-life of approximately 2 minutes due to rapid cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4), and native growth hormone-releasing hormone (GHRH) is degraded within minutes by blood-borne proteases. These short durations are biologically appropriate for moment-to-moment hormonal regulation but are impractical for therapeutic use. The pharmaceutical challenge is to extend half-life without compromising receptor binding or introducing toxicity. Semaglutide exemplifies successful half-life engineering: by substituting amino acids at DPP-4 cleavage sites and attaching a C18 fatty acid chain that binds albumin, its half-life was extended to approximately 165 hours (nearly 7 days), enabling once-weekly dosing. CJC-1295 with DAC achieves a half-life of 6-8 days through its drug affinity complex that binds albumin, compared to the minutes-long half-life of native GHRH. At the other end of the spectrum, smaller peptides like GHRP-6 and BPC-157 have relatively short half-lives (minutes to hours), which is why they are typically administered more frequently — often daily or multiple times daily in research protocols. Stability also extends to storage and formulation: most peptide therapeutics require refrigeration to prevent aggregation and degradation, and lyophilized (freeze-dried) formulations must be reconstituted with bacteriostatic water before use. Temperature excursions, repeated freeze-thaw cycles, and contamination can all compromise peptide integrity. Understanding these stability considerations is essential for anyone working with peptide compounds.

• Endogenous GLP-1 half-life: ~2 minutes vs. Semaglutide: ~165 hours (7 days)
• Native GHRH half-life: minutes vs. CJC-1295 with DAC: 6-8 days
• Short-acting peptides (GHRP-6, BPC-157) typically require daily or more frequent dosing
• Most peptide therapeutics require refrigeration (2-8 degrees C) to maintain stability
• Lyophilized formulations must be properly reconstituted and protected from contamination
• Half-life engineering is the key pharmaceutical advance enabling practical peptide therapeutics

References

1. Peptide-receptor interactions: current knowledge and future directions (2020) — PubMed
2. Mechanisms of peptide hormone action (2009) — PubMed
3. GLP-1 receptor agonists: mechanisms of action (2020) — PubMed
4. Growth hormone secretagogues: history, mechanism of action, and clinical development (2000) — PubMed
5. Peptide drug stability and formulation (2019) — PubMed